Table 3.

Tau modifications following retromer gain-of-function.

Intervention	Model system	Type of tau	∆ tau (detection antibody/fluorophore)	Detection method	Tau aggregation?	Refs.
Vps35 overexpression	3 × Tg mice	Transgenic; human tau P301L (0N4R)	↓ soluble tau (HT7) in cortex	WB	Likely (n.d.)	[154]
			↓ insoluble tau (HT7) in cortex	WB
			↓ p-S202/T205 (AT8) in cortex	WB
			↓ p-T181 (AT270) in cortex	WB
			↓ p-S396/S404 (PHF1) in cortex	WB
			↓ p-S396 (PHF13) in cortex	WB
Vps35 overexpression	Mouse N2a cells	Endogenous	↓ tau (HT7)	WB	No	[104]
			↓ conformational change (MC1)	WB
			↓ p-T181 (AT270)	WB
VPS35 overexpression	HEK293 cells	Transgenic; tau RD (P301L/V337M)-GFP	↓ tau aggregation (GFP)	IF	Yes	[106]
R33	Human IPSC-neurons	Endogenous	↓ p-T231 (AT180)	ELISA	No	[105]
R33	Mouse N2a cells	Endogenous	↓ conformational change (MC1)	WB	No	[104]
			↓ p-T181 (AT270)	WB
			↓ p-S396 (PHF13)	WB
R33	3 × Tg mouse	Transgenic; human tau P301L (0N4R)	↓ p-S202/T205 (AT8)	WB	Likely (n.d.)	[101]
			↓ p-T231 (AT180)	WB
			↓ p-T181 (AT270)	WB
			↓ p-S396 (PHF13)	WB

ELISA enzyme-linked immunosorbent assay, IF immunofluorescence, n.d. not detected, WB western blot.